We are live on ! Find out more
LPCN icon

Lipocine
LPCN

53 hedge funds and large institutions have $94.3M invested in Lipocine in 2016 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

147% more call options, than puts

Call options by funds: $672K | Put options by funds: $272K

13% more funds holding

Funds holding: 47 → 53 (+6)

0% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 17

21% less capital invested

Capital invested by funds: $119M → $94.3M (-$24.5M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
53
Holders Change
+6
Holders Change %
+12.77%
% of All Funds
1.41%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
10
Increased
17
Reduced
17
Closed
4
Calls
$672K
Puts
$272K
Net Calls
+$400K
Net Calls Change
-$286K

Top Buyers

1
GGHC
Gilder Gagnon Howe & Co
New York
+$1.52M
2
TCM
Tang Capital Management
California
+$1M
3
FCMI
Foresite Capital Management III
California
+$674K
4
BG
BlackRock Group
United Kingdom
+$623K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$549K

Top Sellers

1
KCM
Kingdon Capital Management
New York
-$1.86M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.61M
3
LOAMU
Lombard Odier Asset Management (USA)
New York
-$923K
4
VAM
Visium Asset Management
New York
-$733K
5
ISL
Ingalls & Snyder LLC
New York
-$389K
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
1
Invesco
Georgia
$10.9M – – –
VAM
2
Visium Asset Management
New York
$9.18M -$733K -4,298 -7%
VM
3
VHCP Management
New York
$8.63M – – –
RA
4
Royce & Associates
New York
$8.52M +$192K +1,126 +2%
CAM
5
Cormorant Asset Management
Massachusetts
$6.77M – – –
GGHC
6
Gilder Gagnon Howe & Co
New York
$6.64M +$1.52M +8,925 +30%
Vanguard Group
7
Vanguard Group
Pennsylvania
$4.77M +$549K +3,219 +13%
VMI
8
VHCP Management II
New York
$4.26M – – –
FCMI
9
Foresite Capital Management III
California
$4.03M +$674K +3,947 +20%
EI
10
EAM Investors
California
$3.75M -$329K -1,927 -8%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$2.96M +$206K +1,210 +8%
CC
12
Carlson Capital
Texas
$2.75M +$413K +2,419 +18%
RI
13
RTW Investments
New York
$2.44M +$200K +1,172 +9%
BIT
14
BlackRock Institutional Trust
California
$2.27M +$25.1K +147 +1%
Ameriprise
15
Ameriprise
Minnesota
$2.01M -$157K -922 -7%
SM
16
Sabby Management
Florida
$1.53M -$11.4K -67 -0.7%
LOAMU
17
Lombard Odier Asset Management (USA)
New York
$1.21M -$923K -5,408 -44%
TCM
18
Tang Capital Management
California
$1.01M +$1M +5,882 New
DCM
19
DAFNA Capital Management
California
$972K +$459K +2,690 +91%
RFC
20
Russell Frank Company
Washington
$824K -$165K -966 -17%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$811K +$63.5K +372 +9%
Allianz Asset Management
22
Allianz Asset Management
Germany
$741K -$70.3K -412 -9%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$700K +$207K +1,214 +43%
BG
24
BlackRock Group
United Kingdom
$630K +$623K +3,649 New
KCM
25
Kingdon Capital Management
New York
$597K -$1.86M -10,882 -76%
1
2 3

LPCN Hedge Fund Activity: Q1 2016 in Review

53 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2016, worth a combined $94.3M — down 21% from $119M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new LPCN positions and 4 closed out — a net gain of 6 holders — while 17 added to existing stakes and 17 trimmed.

The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $1.52M. The largest seller was Kingdon Capital Management, cutting an estimated $1.86M.

  • 53 institutional investors held Lipocine (LPCN) as of Q1 2016, up from 47 in Q4 2015.
  • Funds reported $94.3M of Lipocine stock for Q1 2016, down 21% quarter-over-quarter.
  • 10 funds opened new Lipocine positions in Q1 2016 and 4 closed out, a net change of +6 holders.
  • The largest Lipocine buyer in Q1 2016 was Gilder Gagnon Howe & Co, an estimated $1.52M added.
  • The largest Lipocine seller in Q1 2016 was Kingdon Capital Management, an estimated $1.86M sold.

Based on aggregated 13F filings for Q1 2016.